Summary
31.97 2.96(10.20%)12/12/2025
Galecto, Inc. (GLTO)
GLTO reported last earnings on 2025-11-06 after the market. An EPS of $-2.36 was observed compared to an estimated EPS of $, resulting in a surprise value of $-2.36. A revenue of $0 million was observed compared to an estimated revenue of $0 million, resulting in a surprise value of $0 Million.
Galecto, Inc. (GLTO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 10.20 | -18.45 | 125.58 | 387.65 | 456.38 | 189.35 | -95.83 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C+ |
| Recommended Rating | Sell |
| DCF | Neutral |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Neutral |
| P/E | Strong Sell |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 31.97 | |
| Open | 27.46 | |
| High | 32.20 | |
| Low | 27.46 | |
| Volume | 93,827 | |
| Change | 2.96 | |
| Change % | 10.20 | |
| Avg Volume (20 Days) | 3,371,296 | |
| Volume/Avg Volume (20 Days) Ratio | 0.03 | |
| 52 Week Range | 2.22 - 33.60 | |
| Price vs 52 Week High | -4.85% | |
| Price vs 52 Week Low | 1,340.09% | |
| Range | 0.00 | |
| Gap Up/Down | -1.26 | |
Profitibility | ||
| Market Capitalization (Mln) | 27 | |
| Revenue per share | 0.0000 | |
| Net Income per share | -11.9394 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -2.4051 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
11/10 13:08 EST - invezz.com
GLTO, MOVE: two penny stocks quadrupled today – but should you buy?
Two obscure US biotech and medtech names – Galecto Inc (NASDAQ: GLTO) and Movano Inc (NASDAQ: MOVE) – stunned markets today with explosive rallies, each surging roughly 300%. While the gains were triggered by company-specific news, the magnitude of the moves has drawn speculative interest from...
GLTO, MOVE: two penny stocks quadrupled today – but should you buy?
Two obscure US biotech and medtech names – Galecto Inc (NASDAQ: GLTO) and Movano Inc (NASDAQ: MOVE) – stunned markets today with explosive rallies, each surging roughly 300%. While the gains were triggered by company-specific news, the magnitude of the moves has drawn speculative interest from...
11/10 11:47 EST - benzinga.com
Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029
Galecto Inc. (NASDAQ:GLTO) stock tripled on Monday, with a session volume of 23.26 million, compared to the average volume of 2.41 million, as per data from Benzinga Pro.
Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029
Galecto Inc. (NASDAQ:GLTO) stock tripled on Monday, with a session volume of 23.26 million, compared to the average volume of 2.41 million, as per data from Benzinga Pro.
11/10 07:00 EST - globenewswire.com
Galecto Announces Acquisition of Damora Therapeutics
Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms
Galecto Announces Acquisition of Damora Therapeutics
Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms
11/06 16:30 EST - globenewswire.com
Galecto Reports Third Quarter 2025 Operating and Financial Results
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results for the quarter ended September 30, 2025.
Galecto Reports Third Quarter 2025 Operating and Financial Results
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results for the quarter ended September 30, 2025.
10/07 13:05 EST - benzinga.com
What's Going On With Nano-Cap Galecto Stock On Tuesday?
Galecto Inc. (NASDAQ:GLTO) stock spiked on Tuesday, with a session volume of 61.11 million, compared to the average volume of 984,320, as per data from Benzinga Pro.
What's Going On With Nano-Cap Galecto Stock On Tuesday?
Galecto Inc. (NASDAQ:GLTO) stock spiked on Tuesday, with a session volume of 61.11 million, compared to the average volume of 984,320, as per data from Benzinga Pro.
10/07 10:27 EST - invezz.com
Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble
Galecto stock (NASDAQ: GLTO) went absolutely bonkers on Tuesday, surging over 600% in what might be one of the wildest rallies we have seen from a small biotech in recent memory. The shares jumped from a close of $3.71 the day before to an intraday high around $25.99, fueled by a massive pre-market...
Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble
Galecto stock (NASDAQ: GLTO) went absolutely bonkers on Tuesday, surging over 600% in what might be one of the wildest rallies we have seen from a small biotech in recent memory. The shares jumped from a close of $3.71 the day before to an intraday high around $25.99, fueled by a massive pre-market...
08/05 16:15 EST - globenewswire.com
Galecto Reports Second Quarter 2025 Operating and Financial Results
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended June 30, 2025.
Galecto Reports Second Quarter 2025 Operating and Financial Results
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended June 30, 2025.
06/11 03:34 EST - https://www.defenseworld.net
12,701 Shares in Galecto, Inc. (NASDAQ:GLTO) Bought by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new position in shares of Galecto, Inc. (NASDAQ:GLTO – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,701 shares of the company’s stock, valued at...
12,701 Shares in Galecto, Inc. (NASDAQ:GLTO) Bought by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new position in shares of Galecto, Inc. (NASDAQ:GLTO – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,701 shares of the company’s stock, valued at...
05/08 16:30 EST - globenewswire.com
Galecto Reports First Quarter 2025 Operating and Financial Results
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025.
Galecto Reports First Quarter 2025 Operating and Financial Results
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025.
03/19 16:45 EST - globenewswire.com
Galecto Reports Full-Year 2024 Financial Results
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.
Galecto Reports Full-Year 2024 Financial Results
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.
02/06 08:00 EST - globenewswire.com
Galecto to Participate in Upcoming Investor Conferences
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor...
Galecto to Participate in Upcoming Investor Conferences
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor...
11/14 10:56 EST - zacks.com
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Galecto (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Galecto (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
11/01 08:30 EST - globenewswire.com
Galecto Reports Third Quarter 2024 Financial Results
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines - Appointed Dr. Amy Wechsler to the Board of Directors and Matthew...
Galecto Reports Third Quarter 2024 Financial Results
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines - Appointed Dr. Amy Wechsler to the Board of Directors and Matthew...
10/15 08:30 EST - globenewswire.com
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique...
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique...
10/07 08:45 EST - globenewswire.com
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to focus on cancer and...
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to focus on cancer and...
08/28 09:00 EST - globenewswire.com
Galecto Announces Reverse Stock Split
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that it will implement a 1-for-25 Reverse Stock Split of its common stock (the “Reverse Stock...
Galecto Announces Reverse Stock Split
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that it will implement a 1-for-25 Reverse Stock Split of its common stock (the “Reverse Stock...
05/01 16:01 EST - globenewswire.com
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto's GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma...
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto's GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma...
02/14 13:01 EST - zacks.com
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Market News
×
Loading news…